Harry Adolph Drabkin
Physician at President St, Charleston, SC
License number
Colorado 23204
Issued Date
Jul 24, 1980
Renew Date
May 1, 2015
Expiration Date
Apr 30, 2017
Type
Physician
Address
Address
340 President St, Charleston, SC 29403
Personal information
See more information about Harry Adolph Drabkin at radaris.comName
Address
Phone
340 President St, Charleston, SC 29403
340 President St, Charleston, SC 29403
Professional information
See more information about Harry Adolph Drabkin at trustoria.com
Dr. Harry A Drabkin, Charleston SC - MD (Doctor of Medicine)
Dr. Harry A Drabkin, Charleston SC - MD (Doctor of Medicine)
Specialties:
Oncology, Medical Oncology
Address:
MUSC Hollings Cancer Center
86 Jonathan Lucas St, Charleston 29425
(843) 792-9300 (Phone)
Medical University Of SC HO
96 Jonathan Lucas St #HOLLINGS C, Charleston 29425
(843) 792-4271 (Phone)
Medical Univ SC Hmtlgy Onlgy
96 Jonathan Lucas St #CSB903, Charleston 29425
(843) 792-4271 (Phone)
86 Jonathan Lucas St, Charleston 29425
(843) 792-9300 (Phone)
Medical University Of SC HO
96 Jonathan Lucas St #HOLLINGS C, Charleston 29425
(843) 792-4271 (Phone)
Medical Univ SC Hmtlgy Onlgy
96 Jonathan Lucas St #CSB903, Charleston 29425
(843) 792-4271 (Phone)
Certifications:
Internal Medicine, 1980, Medical Oncology, 1983
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
MUSC Hollings Cancer Center
86 Jonathan Lucas St, Charleston 29425
Medical Univ SC Hmtlgy Onlgy
96 Jonathan Lucas St #CSB903, Charleston 29425
Medical University Of SC HO
96 Jonathan Lucas St #HOLLINGS C, Charleston 29425
Musc Medical Center
169 Ashley Ave, Charleston 29425
86 Jonathan Lucas St, Charleston 29425
Medical Univ SC Hmtlgy Onlgy
96 Jonathan Lucas St #CSB903, Charleston 29425
Medical University Of SC HO
96 Jonathan Lucas St #HOLLINGS C, Charleston 29425
Musc Medical Center
169 Ashley Ave, Charleston 29425
Education:
Medical School
University of Kansas / School of Medicine
Graduated: 1977
Cincinnati Med Ctr
Colo Hlth Scis Ctr
University of Kansas / School of Medicine
Graduated: 1977
Cincinnati Med Ctr
Colo Hlth Scis Ctr
Harry A Drabkin, Charleston SC
Harry A Drabkin, Charleston SC
Specialties:
Oncologist
Address:
171 Ashley Ave, Charleston, SC 29425
Education:
University of Kansas, School of Medicine - Doctor of Medicine
University of Colorado Hospital-Anschutz Inpatient Pavilion - Fellowship - Hematology and Oncology (Internal Medicine)
University Hospital of Cincinnati - Residency - Internal Medicine
University of Colorado Hospital-Anschutz Inpatient Pavilion - Fellowship - Hematology and Oncology (Internal Medicine)
University Hospital of Cincinnati - Residency - Internal Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Oncology (Internal Medicine)
Egfr Inhibitor Therapy Responsiveness
Egfr Inhibitor Therapy Responsiveness
US Patent:
2011029, Dec 1, 2011
Filed:
Sep 11, 2009
Appl. No.:
13/063260
Inventors:
Harry A. Drabkin - Charleston SC, US
Robert M. Gemmill - Charleston SC, US
Federico R. Cappuzzo - Denver CO, US
Wan Lam - Vancouver, CA
Robert M. Gemmill - Charleston SC, US
Federico R. Cappuzzo - Denver CO, US
Wan Lam - Vancouver, CA
International Classification:
C40B 30/04, C12Q 1/68, C40B 40/06
US Classification:
506 9, 506 16, 435 611
Abstract:
Disclosed is the identification, provision and use of biomarkers predictive of sensitivity or resistance to EGFR inhibitors such as gefitinib and products and processes related thereto. Specifically, a method is described for selecting a cancer patient who is predicted to benefit from therapeutic administration of an EGFR inhibitor, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitor. Also described is a method to identify molecules that interact with the EGFR pathway to allow or enhance responsiveness to EGFR inhibitors, as well as a plurality of polynucleotides or antibodies for the detection of the copy number or expression of genes that are indicative of sensitivity or resistance to EGFR inhibitors, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitors. A method to identify a compound with the potential to enhance the efficacy of EGFR inhibitors is also described.
Histone Deacetylase Inhibitors Sensitize Cancer Cells To Epidermal Growth Factor Inhibitors
Histone Deacetylase Inhibitors Sensitize Cancer Cells To Epidermal Growth Factor Inhibitors
US Patent:
2008018, Jul 31, 2008
Filed:
Sep 25, 2007
Appl. No.:
11/861033
Inventors:
Samir E. Witta - Greenwood Village CO, US
Paul A. Bunn - Steamboat Springs CO, US
Harry A. Drabkin - Charleston SC, US
Robert M. Gemmill - Charleston SC, US
Daniel Chuen-Fong Chan - Denver CO, US
Paul A. Bunn - Steamboat Springs CO, US
Harry A. Drabkin - Charleston SC, US
Robert M. Gemmill - Charleston SC, US
Daniel Chuen-Fong Chan - Denver CO, US
International Classification:
A61K 31/498, A61K 31/4406
US Classification:
51426624, 514357
Abstract:
Disclosed is the use of a combination of histone deacetylase inhibitors and kinase inhibitors with anti-EGFR activity.
Histone Deacetylase Inhibitors Sensitize Cancer Cells To Epidermal Growth Factor Inhibitors
Histone Deacetylase Inhibitors Sensitize Cancer Cells To Epidermal Growth Factor Inhibitors
US Patent:
2008023, Sep 25, 2008
Filed:
Mar 13, 2006
Appl. No.:
11/908388
Inventors:
Samir E. Witta - Greenwood Village CO, US
Paul A. Bunn - Steamboat Springs CO, US
Harry A. Drabkin - Charleston SC, US
Robert M. Gemmill - Charleston SC, US
Daniel Chuen-Fong Chan - Denver CO, US
Paul A. Bunn - Steamboat Springs CO, US
Harry A. Drabkin - Charleston SC, US
Robert M. Gemmill - Charleston SC, US
Daniel Chuen-Fong Chan - Denver CO, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF COLORADO - Denver CO
International Classification:
A61K 31/16, A61K 31/19, A61K 31/27, A61K 31/395, A61K 31/5377, A61K 31/517, C12Q 1/68
US Classification:
5142345, 514575, 514557, 514487, 514183, 5142664, 435 6
Abstract:
Disclosed is the use of a combination of histone deacetylase inhibitors and epidermal growth factor receptor (EGFR) inhibitors to treat cancer.